腫瘍向けコンパニオン診断検査：グローバル企業動向...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents2
1.1 List of Tables 4
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
3 Competitive Assessment 13
3.1 Overview 13
3.2 Techniques in Use by Currently Marketed Products 13
3.2.1 Immunohistochemistry 13
3.2.2 Fluorescence In Situ Hybridization 13
3.2.3 Polymerase Chain Reaction 14
3.3 Competitive Analysis 14
3.3.1 Breast Cancer Companion Diagnostic Tests 14
3.3.2 Colorectal Cancer Companion Diagnostic Tests 43
3.3.3 Melanoma Companion Diagnostic Tests 52
3.3.4 Non-Small Cell Lung Cancer Companion Diagnostic Tests 58
4 Pipeline Products 75
4.1 Overview 75
4.2 Pipeline by Phase of Development 77
4.3 Pipeline Product Profiles 78
4.3.1 Breast Cancer Companion Diagnostic Tests 78
4.3.2 Colorectal Cancer Companion Diagnostic Tests 86
4.3.3 Melanoma Companion Diagnostic Tests 92
4.3.4 Non-Small Cell Lung Cancer Companion Diagnostic Tests 99
5 Current and Future Players 114
5.1 Trends in Corporate Strategy 114
5.1.1 Companion Diagnostics Business Models 114
5.2 Company Profiles 115
5.2.1 Pharmaceutical/Therapy Companies Developing Companion Diagnostic Tests 115
5.2.2 Diagnostics Companies Developing Companion Diagnostic Tests (in Partnership with Pharmaceutical Companies) 169
6 Appendix 252
6.1 Bibliography 252
6.2 Abbreviations 271
6.3 Report Methodology 273
6.3.1 Coverage 273
6.3.2 Secondary Research 274
6.3.3 Forecasting Methodology 274
6.4 Physicians Included in this Study 276
6.5 About the Authors 278
6.5.1 Andrew Thompson, Ph.D., Senior Analyst, In Vitro Diagnostics 278
6.5.2 Derek Archila, MBA, Lead Analyst, Medical Devices 278
6.5.3 Bonnie Bain, PhD, Global Head of Healthcare 279
6.6 Disclaimer 280